Promising Off-the-Shelf Cancer Vaccine Extends Survival and Prevents Recurrence
TL;DR Summary
An experimental off-the-shelf cancer vaccine called ELI-002 shows promising early results in prolonging survival and inducing immune responses in patients with pancreatic and colorectal cancers harboring KRAS mutations, with further trials underway to confirm its efficacy.
- Experimental ‘Off-the-Shelf’ Cancer Vaccine Is Already Prolonging Lives, Study Suggests Gizmodo
- Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results Nature
- Off-the-shelf vaccine shows promise in preventing cancers returning, study finds The Guardian
- Pancreatic cancer vaccine prevents recurrence in Phase 1 clinical trial NBC News
- The 6 signs of pancreatic cancer to never ignore The Independent
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
93%
528 → 36 words
Want the full story? Read the original article
Read on Gizmodo